{"type":"trials","record":{"id":42029,"source_id":"clinicaltrials-gov","external_id":"NCT05131646","title":"Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study","brief_summary":"This is an open-label, non-interventional extension study of up to 12 weeks in duration in subjects completing Cohorts 2, 3, and 4 of the Parent study, CLS1002-101.","overall_status":"Completed","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Clearside Biomedical, Inc.","enrollment":15,"countries":["United States"],"start_date":"2021-10-08","completion_date":"2023-01-05","last_update_date":"2024-03-04","source_url":"https://clinicaltrials.gov/study/NCT05131646","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Clearside Biomedical, Inc.","interventions":["CLS-AX"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of Participants With Treatment-emergent Adverse Events (TEAEs) — Day 1 to Week 24","Number of Participants With Serious Adverse Events (SAEs) — Day 1 to Week 24","Mean Change From Baseline in Central Subfield Thickness (CST) in the Study Eye — Weeks 4, 8, 12, 16, 20 and 24","Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye — Weeks 4, 8, 12, 16, 20…","Number of Participants Receiving Additional Intravitreal (IVT) Aflibercept Injections — Day 1 to Week 24"],"design_description":null,"source_has_results":true},"controlled_terms":["Neovascular Age-related Macular Degeneration","CLS-AX"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05131646","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2021-10-08 to 2023-01-05","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.909Z","intervention":["CLS-AX"],"participants":15,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of Participants With Treatment-emergent Adverse Events (TEAEs) — Day 1 to Week 24","Number of Participants With Serious Adverse Events (SAEs) — Day 1 to Week 24","Mean Change From Baseline in Central Subfield Thickness (CST) in the Study Eye — Weeks 4, 8, 12, 16, 20 and 24","Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye — Weeks 4, 8, 12, 16, 20…","Number of Participants Receiving Additional Intravitreal (IVT) Aflibercept Injections — Day 1 to Week 24"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42029","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}